If you liked this article you might like

Abbvie Plans to Defend Humira, Sees Upside in Oncology and Hep C Treatments
Hep C Business Slow-Down Could Hamper Bristol-Myers' Future
Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers
Bristol-Myers (BMY) Stock Slides Despite Q2 Earnings, Revenue Beat